Target Nutra

About Target HF2C

Obtaining Target preparations

An announcement will be made on the main (Home) page when Target preparations are available.

HF2C Summary, Some Reports

HF2C is typically applied 2-4x daily from the earliest symptoms of viral activity, or used once daily to prevent outbreaks.

HF2C should be applied as early as possible during an outbreak. The quantity provided is small but a little HF2C goes a long way. For sporadic outbreaks, say two a year, the bottle could last several years. If you suffer from frequent outbreaks (i.e. only a few weeks between them) please see the trial invitation.

To prevent an outbreak, particularly useful if there is an important event coming up, HF2C can be applied once daily for a few days beforehand.

HF2C contains a little under 10% Melissa officinalis concentrate (the herb commonly known as Lemon Balm). All the other ingredients can be found in cosmetic products and foodstuffs. There is nothing remotely toxic. Nonetheless the disclaimer at the bottom of the Trials page applies. The chief risk is of an allergic reaction to the Melissa.

It might be mentioned that the vast majority of "Melissa" products are not Melissa officinalis at all. The yield from Melissa officinalis leaves is extremely low so its concentrate is expensive. Even some high-priced "Melissa" products are actually a blend of other herbal oils. "Melissa" seems to have become the generic name for everyone's favourite herbal oil mixture.

HF2C combines the known benefits of Melissa officinalis with the results of original research. It is unclear at this stage whether it is most effective against HSV-1 (generally, upper body infections, of which cold sores are typical) or HSV-2 (generally, lower body infections).

A small number of participants have made comments which suggested that HF2C had achieved a longer-term effect, e.g. "Any outbreaks I've had have been less severe and I'm getting fewer at the moment too" and "I cannot believe I have gone so long without an outbreak." While there is a theoretical basis for such effects, there is certainly not enough evidence to make any claim in this regard. If there is a longer-term effect of the Target preparations -- which has yet to be established -- it will likely only apply to a minority.

A few participants reported that HF2C had little or no effect: nothing works for everyone. For the remainder, based on their comments, a 50% average reduction in outbreak duration using HF2C is a reasonable claim. This compares to about 15% for topical aciclovir (Zovirax, Virasorb etc.). When the preparation is applied early, complete suppression of an outbreak can be achieved.

A Notable Report

A Notable Email